当代医学
噹代醫學
당대의학
CHINA CONTEMPORARY MEDICINE
2013年
8期
92
,共1页
慢性乙型肝炎%肝硬化%阿德福韦酯%拉米夫定
慢性乙型肝炎%肝硬化%阿德福韋酯%拉米伕定
만성을형간염%간경화%아덕복위지%랍미부정
Chronic hepatitis B%Cirrhosis%Adefovir dipivoxil%Lamivudine
目的探讨阿德福韦酯(ADV)与拉米夫定(LAM)治疗乙型肝炎肝硬化的临床疗效和安全性.方法选取乙型肝炎肝硬化患者86例,分为两组,各43例.对照组给予常规保肝治疗,观察组给予ADV和LAM治疗,均连续24周.治疗前后观察肝功能、HBV-DNA定量和不良反应情况.结果观察组与对照组总有效率为90.70%和79.07%,差异有统计学意义(P<0.05).治疗后,两组患者ALT、TbiL、HBV-DNA均较治疗前改善,且观察组改善程度优于对照组,差异有统计学意义(P<0.01).观察组与对照组不良反应发生率分别为6.98%和4.65%,差异无统计学意义(P>0.05).结论阿德福韦酯与拉米夫定治疗乙型肝炎肝硬化具有疗效明确,快速清除病毒,安全性高等特点,值得基层医疗机构推广应用.
目的探討阿德福韋酯(ADV)與拉米伕定(LAM)治療乙型肝炎肝硬化的臨床療效和安全性.方法選取乙型肝炎肝硬化患者86例,分為兩組,各43例.對照組給予常規保肝治療,觀察組給予ADV和LAM治療,均連續24週.治療前後觀察肝功能、HBV-DNA定量和不良反應情況.結果觀察組與對照組總有效率為90.70%和79.07%,差異有統計學意義(P<0.05).治療後,兩組患者ALT、TbiL、HBV-DNA均較治療前改善,且觀察組改善程度優于對照組,差異有統計學意義(P<0.01).觀察組與對照組不良反應髮生率分彆為6.98%和4.65%,差異無統計學意義(P>0.05).結論阿德福韋酯與拉米伕定治療乙型肝炎肝硬化具有療效明確,快速清除病毒,安全性高等特點,值得基層醫療機構推廣應用.
목적탐토아덕복위지(ADV)여랍미부정(LAM)치료을형간염간경화적림상료효화안전성.방법선취을형간염간경화환자86례,분위량조,각43례.대조조급여상규보간치료,관찰조급여ADV화LAM치료,균련속24주.치료전후관찰간공능、HBV-DNA정량화불량반응정황.결과관찰조여대조조총유효솔위90.70%화79.07%,차이유통계학의의(P<0.05).치료후,량조환자ALT、TbiL、HBV-DNA균교치료전개선,차관찰조개선정도우우대조조,차이유통계학의의(P<0.01).관찰조여대조조불량반응발생솔분별위6.98%화4.65%,차이무통계학의의(P>0.05).결론아덕복위지여랍미부정치료을형간염간경화구유료효명학,쾌속청제병독,안전성고등특점,치득기층의료궤구추엄응용.
Objective To explore the effect and safety of treating hepatitis b cirrhosis by Adefovir (ADV) and Lamivudine (LAM).Methods 86 patients with hepatitis b cirrhosis were selected,and divided into observation group and control group,43 cases per group.Patients in control group were given conventional treatment,yet patients in observation group were given ADV and LAM,and they were all treated for 24 weeks.Liver function,HBV DNA quantitative and adverse reaction were tested before and after treatment.Results Total effective rate in observation group and control group were 90.70% and 79.07% (P<0.05). Liver function and HBV DNA quantitative in two groups were improved after treatment (P<0.05),and observation group’s effect was superior than that of control group(P<0.01).Adverse reaction rate in observation group and control group were 6.98%and 4.65%(P>0.05).Conclusion It has high clinical efficiency of treating hepatitis b cirrhosis by ADV and LAM,and it eliminates HBV rapidly,also with higher security,so it is suitable for hepatitis b cirrhosis’s clinical treatment.